Insider · SEC Form 4 filer
Ilya Rachman
Past buys: 3 of 3 beat
Companies
Where they file as an insider
Immix Biopharma (IMMX) CEO and Chairman, Director Latest filing Dec 10, 2025
Track record
Did their buys beat the typical stock?
Open-market buys6
Quarters checked 6 months later3
Beat the typical stock 3 of 3
Quarters too new to check0
3 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Immix Biopharma (IMMX) Bought Dec 10, 2025 · $4.98K · 746 shares Beat typical Dec 31, 2025 $5.23 → Jun 30, 2026 $10.31 · +97.1% (typical stock +4.7%)
Immix Biopharma (IMMX) Bought Sep 17, 2025 · $5.05K · 2,500 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2025 and Mar 31, 2026.
Immix Biopharma (IMMX) Bought Jun 18, 2025 · $5.01K · 2,178 shares Beat typical Jun 30, 2025 $2.07 → Dec 31, 2025 $5.23 · +152.7% (typical stock +2.1%)
Immix Biopharma (IMMX) Bought May 14–Jun 7, 2024 · $21.2K · 10,200 shares Beat typical Jun 30, 2024 $1.98 → Dec 31, 2024 $2.20 · +11.1% (typical stock +3.9%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.